SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : PFE (Pfizer) How high will it go?
PFE 25.88+1.5%Nov 12 3:59 PM EST

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: BigKNY3 who wrote (7626)5/7/1999 7:46:00 AM
From: Mkilloran  Read Replies (2) of 9523
 
BiKNY3....the point of the study is simple for those that failed or could not tolerate Viagra there is an alternative solution that works in a good percent of these patients.

This is a niche market for Muse. The patient does not have to continue to be impotent.

In addition to this group those patients on NTG that should not use Viagra have an alternative with Muse.

An additional abstract was presented at the AUA meeting using a combination of Viagra and MUSE.

Viagra has the majority of the ED patients..

.Muse can capture 15% of the ED patients.

Leaving some smaller portion with yet an other alternative that is a more intrusive method for the patient ,Caverject needle injection.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext